contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alzinova-to-attend-bio-europe-2024-europes-leading-partnering-conference-for-the-life-science-industry

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Alzinova

Alzinova AB (publ) (ticker: ALZ), a Swedish biopharma company specializing in the development of innovative therapies against Alzheimer's disease, today announces that it will participate at...

<div class="mfn-preamble"><p><strong>Alzinova AB (publ) (ticker: ALZ), a Swedish biopharma company specializing in the development of innovative therapies against Alzheimer's disease, today announces that it will participate at BIO-Europe 2024, which will take place November 4-6 in Stockholm, Sweden. BIO-Europe is Europe's largest partnering conference in life science and attracts leading actors from all over the world.</strong></p></div><div class="mfn-body"><p>The conference offers a platform for companies like Alzinova to present their research and development to potential partners and investors. Focusing on Alzinova's innovative vaccine candidate, ALZ-101, which is aimed at neutralizing the toxic oligomeric forms of amyloid-beta – a key component in the development of Alzheimer's disease – the company looks forward to deepening contacts and exploring strategic collaborations.</p><p><em>"We are very much looking forward to attending BIO-Europe 2024. This is a fantastic opportunity to showcase our latest research and development, and to discuss possible partnerships to advance our drug candidate ALZ-101 into new clinical trials," </em>comments Tord Labuda, CEO Alzinova AB.</p><p>During the year, Alzinova has reported progress in the development of ALZ-101, where positive results from ongoing clinical studies strengthen the company's position in Alzheimer's research. At BIO-Europe, Alzinova will conduct meetings with potential partners in the pharmaceutical industry, research institutions and investors to advance the development of its therapies against Alzheimer's disease. BIO-Europe is known for its effective partnering meetings and opportunities to create long-term collaborations in the biotechnology and pharmaceutical sectors.</p><p><strong>For more information, please contact:</strong><br>Tord Labuda, CEO<br>Tel: +46 (0)70 838 23 23<br>E-mail: tord.labuda@alzinova.com</p><p><strong>About Alzinova</strong><br>Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: <a rel="noopener" href="http://www.alzinova.com/">www.alzinova.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/553baac9-1a26-4ee7-899b-fb49e65324c0/alzinova-to-attend-bio-europe-2024-europes-leading-partnering-conference-for-the-life-science-industry.pdf" class="mfn-generated mfn-primary">Alzinova to attend BIO-Europe 2024 - Europe's leading partnering conference for the life science industry</a></p></div>

Alzinova to attend BIO-Europe 2024 - Europe's leading partnering conference for the life science industry